Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
宜明昂科生物醫藥技術（上海）股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 1541)

(1) RESIGNATION OF NON-EXECUTIVE DIRECTOR; AND (2) CHANGE IN COMPOSITION OF AUDIT COMMITTEE AND REMUNERATION COMMITTEE

The board (the "**Board**") of directors (the "**Directors**", each a "**Director**") of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the "**Company**", together with its subsidiaries, the "**Group**") announces the following changes to the Board and its committees:

RESIGNATION OF NON-EXECUTIVE DIRECTOR

Dr. Xu Cong ("**Dr. Xu**") has tendered his resignation as a non-executive Director of the Company in order to devote more time to his other business commitments with effect from November 24, 2026 (the "**Resignation**"). Following the Resignation, Dr. Xu will cease to be a member of each of the audit committee (the "**Audit Committee**") and the remuneration committee (the "**Remuneration Committee**") of the Board.

Dr. Xu has confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the shareholders of the Company (the "**Shareholders**").

The Board is currently identifying a suitable candidate to fill the vacancy on the Board. The Company will complete the procedures for appointment of a new Director as soon as practicable in accordance with relevant rules and make further announcement as and when appropriate.

The Board would like to express its sincere gratitude to Dr. Xu for his valuable contribution to the Company during his tenure of service.

CHANGE IN COMPOSITION OF AUDIT COMMITTEE AND REMUNERATION COMMITTEE

Following the Resignation, Dr. Xu will cease to be a member of each of the Audit Committee and the Remuneration Committee.

The Board is pleased to announce that, Ms. Fu Dawei, a non-executive Director, has been appointed as a member of the Audit Committee and the Remuneration Committee with effect from November 24, 2026.

By order of the Board
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
宜明昂科生物醫藥技術(上海)股份有限公司
Tian Wenzhi
Chairman and Executive Director

Shanghai, the PRC, November 24, 2026

As at the date of this announcement, the Board of Directors comprises (i) Dr. Tian Wenzhi, Mr. Li Song, Ms. Guan Mei and Mr. Zhang Ruliang as executive Directors; (ii) Ms. Fu Dawei as non-executive Director; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.